HK inno.N Corporation

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study to Evaluate the Pharmacokinetic Characteristics and Safety of IN-C004 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: IN-C004 with water
Drug: IN-C004 without water
Drug: K-CAB tab. with water

First Posted Date: 2020-12-04

Last Posted Date: 2021-03-29

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 48

Registration Number: NCT04654078

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of

Pharmacokinetic Interaction Between Tegoprazan and NSAIDs After Multiple Oral Dosing in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Naproxen
Drug: Tegoprazan
Drug: Aceclofenac
Drug: Celecoxib

First Posted Date: 2020-11-23

Last Posted Date: 2020-11-23

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 60

Registration Number: NCT04639804

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of

Safety and Immunogenicity of High-dose IN-B001 in Healthy Subjects

Phase 1

Conditions: Hand, Foot and Mouth Disease

Interventions: Biological: IN-B001 Bivalent C dose
Biological: IN-B001 EV71 A dose
Biological: IN-B001 CVA16 B dose
Biological: Placebo

First Posted Date: 2020-11-20

Last Posted Date: 2020-11-20

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 30

Registration Number: NCT04637919

Locations: 🇰🇷
Seoul National University Hospital, Clinical Trial Center, Seoul, Korea, Republic of

A Study to Explore Pharmacokinetics/Pharmacodynamics and Safety of Tegoprazan BID Dosing in Healthy Subjects

Phase 1

Conditions: Healthy

Interventions: Drug: Tegoprazan dose B or placebo
Drug: Tegoprazan dose A or placebo
Drug: Tegoprazan dose C or placebo
Drug: Tegoprazan dose D or placebo

First Posted Date: 2020-10-14

Last Posted Date: 2020-12-28

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 40

Registration Number: NCT04587011

Locations: 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of

A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls

Phase 1

Conditions: Hepatic Impairment
Healthy

Interventions: Drug: Tegoprazan 50mg

First Posted Date: 2020-07-31

Last Posted Date: 2020-11-09

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 28

Registration Number: NCT04494269

Locations: 🇰🇷
CHA Bundang Medical Center, Seongnam-si, Korea, Republic of
🇰🇷
Gachon University Gil Medical Center, Incheon, Korea, Republic of
🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Bioequivalence and Safety Study of IN-A012 and Akynzeo Capsules in Male and Female Healthy Korean Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: IN-A012
Drug: Akynzeo 300Mg-0.5Mg Capsule

First Posted Date: 2020-07-24

Last Posted Date: 2021-06-01

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 44

Registration Number: NCT04486157

Locations: 🇰🇷
Catholic Univ. of Seoul St. Mary's Hospital, Seoul, Korea, Republic of

A Study to Evaluate Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of IN-C005 in Healthy Male Subjects

Phase 1

Conditions: Healthy

Interventions: Drug: IN-C005 dose E
Drug: IN-C005 dose B
Drug: IN-C005 dose D
Drug: IN-C005 dose A
Drug: IN-C005 dose C
Drug: IN-C005 dose F

First Posted Date: 2020-07-24

Last Posted Date: 2020-11-09

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 42

Registration Number: NCT04485884

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Study to Evaluate the Efficacy and Safety of Tegoprazan in ERD Patients With Nighttime Heartburn and Sleep Disturbance

Phase 4

Completed

Conditions: Erosive Reflux Disease

Interventions: Drug: Esomeprazole
Drug: Tegoprazan

First Posted Date: 2020-03-17

Last Posted Date: 2022-02-25

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 46

Registration Number: NCT04309916

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of

Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CJ-15314 Phosphate in Healthy Male Subjects

Phase 1

Conditions: Healthy

Interventions: Drug: A dose as CJ-15314
Drug: B dose as CJ-15314
Drug: C dose as CJ-15314
Drug: D dose as CJ-15314
Drug: E dose as CJ-15314
Drug: F dose as CJ-15314
Drug: Placebo

First Posted Date: 2020-03-06

Last Posted Date: 2020-03-06

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 55

Registration Number: NCT04297865

Locations: 🇰🇷
Seoul National University Hospital, Dept. of Clinical Pharmacology, Seoul, Korea, Republic of

Study to Evaluate the Pharmacodynamics After Single Oral Dosing of Tegoprazan, EAPA115 and RAPA115 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tegoprazan 50 mg
Drug: EAPA115
Drug: RAPA115

First Posted Date: 2020-01-18

Last Posted Date: 2020-12-01

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 19

Registration Number: NCT04231136

Locations: 🇰🇷
Seoul National University Hospital, Clinical Trial Center, Seoul, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy